ChemGenex Pharmaceuticals Limited (ChemGenex) is an integrated biopharmaceutical development company with expertise in the discovery and the development of oncology drugs. As of June 30, 2008, ChemGenex had two small molecule drug candidates in human clinical trials (Omacetaxine, formerly called Ceflatonin in phase II/III and Quinamed in phase II) and a pipeline of development-stage compounds and targets, including CXS299 and CXS2101. ChemGenex focuses to develop targeted medicines for the treatment of cancer by identifying and targeting the genetic components of a range of cancer types. Autogen Research Pty Ltd was demerged on December 13, 2007. The company has two molecules in clinical trials and has a supporting suite of pre-clinical anti-cancer compounds in development. In June 2008, the Company announced that it had acquired commercialization rights for Omacetaxine from its development partner Stragen Pharma.
(Source: ARS)
